Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.

Joachim  Aerts

Stock and Other Ownership Interests  - amphera

Consulting or Advisory Role - Amphera; AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novocure

Research Funding - AstraZeneca (Inst); Nutricia (Inst)

Patents, Royalties, Other Intellectual Property - cdendritic cel based immunotherapy (Inst); combination immunotherapy (Inst); proteomics in nsclc (Inst)

(OPTIONAL) Uncompensated Relationships - IASLC; IMIG

Luis G.  Paz-Ares

Leadership - ALTUM Sequencing; Stab Therapeutics

Stock and Other Ownership Interests  - Altum Sequencing; Stab therapeutics

Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda

Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda

Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech

Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)

Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)

Carole  Helissey

Honoraria - Accord Healthcare; Astellas Pharma; AstraZeneca; Bayer; BMSi; GlaxoSmithKline; Ipsen; Janssen; MSD Oncology; Pfizer; Viatris

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BMSi; Janssen; MSD Oncology; Pfizer

Travel, Accommodations, Expenses - AstraZeneca; Bayer; Janssen; Pfizer

Federico  Cappuzzo

Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; bristol-myers; Lilly; MSD Oncology; Novocure; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Takeda

Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Lilly; MSD Oncology; Novocure; pfizer; PharmaMar; Roche/Genentech; Sanofi; Takeda

Travel, Accommodations, Expenses - OSE Immunotherapeutics

Gilles  Quere

No Relationships to Disclose

Dariusz  Kowalski

Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Johnson & Johnson/Janssen; Merck Serono; MSD; Pfizer; Roche/Genentech; Sanofi/Aventis; Takeda

Jose Carlos  Benitez

Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst)

Travel, Accommodations, Expenses - AstraZeneca Spain; AstraZeneca Spain; Daiichi Sankyo/Astra Zeneca; Roche; Sanofi; Takeda

Florian  Guisier

Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Janssen; MSD; Pfizer; Roche; Sanofi; Takeda; Viatris

Consulting or Advisory Role - Amgen; AstraZeneca; BMS GmbH & Co. KG; MSD; Roche; Sanofi

Research Funding - Pfizer (Inst); Roche (Inst); Takeda (Inst)

Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD; Takeda

Benjamin  Besse

Honoraria - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Hedera Dx (Inst); Janssen (Inst); MSD (Inst); Roche (Inst); Sanofi/Aventis (Inst); Springer Healthcare Ltd (Inst)

Consulting or Advisory Role - Abbvie (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CureVac (Inst); Da voltera (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); F. Hoffmann LaRoche (Inst); Genmab (Inst); Immunocore (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); OSE Immunotherapeutics (Inst); Owkin (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); Taiho Oncology (Inst); Turning Point Therapeutics (Inst)

Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Enliven Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); PharmaMar (Inst); Prelude Therapeutics (Inst); Roche/Genentech (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)

Shirish M.  Gadgeel

Honoraria - Merck

Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Daichii-Sanyko; Eisai; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Regeneron; Takeda

Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); Daichii Sanyko (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Dragonfly Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); I-Mab (Inst); Incyte (Inst); InventisBio (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Nektar (Inst); Numab (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); Ymabs Therapeutics Inc (Inst)

Travel, Accommodations, Expenses - Mirati Therapeutics

Other Relationship - AstraZeneca

Thomas  Wehler

Honoraria - Abbvie; Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda

Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda

Ignacio  Gil-Bazo

Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; MSD; Roche; Sanofi; Takeda

Consulting or Advisory Role - Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; MSD; Roche; Sanofi; Takeda

Research Funding - Merck (Inst)

Michael Jon  Chisamore

Employment - Merck

Stock and Other Ownership Interests  - Merck

Cem  Gorgun

Employment - BioNTech SE

Stock and Other Ownership Interests  - BioNTech SE

Ilhan  Celik

No Relationships to Disclose

Marie  Holst Mørch

Employment - Genmab

Stock and Other Ownership Interests  - Genmab

Patricia  Garrido Castro

Employment - Genmab

Stock and Other Ownership Interests  - Genmab

Teng Jin  Ong

Employment - Genmab

Stock and Other Ownership Interests  - Genmab

Enriqueta  Felip

Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics

Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Peervoice; Pfizer; Roche; Sanofi; Takeda; Touch Oncology

Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche

Other Relationship - GRIFOLS

(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023